Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban in recent acute coronary syndrome
ACTRN12607000405415Phase 2Completed
- Sponsor
- Bayer
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of rivaroxaban in acute coronary syndrome (ACS) (4 arms), sponsored by Bayer. Primary endpoint: Protocol-defined clinically significant bleeding. Started Nov 2006; status: completed.
02
Drugs
rivaroxaban
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ACTRN12607000405415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000405415.